| |OCTOBER 20248BOSTON SCIENTIFIC BAGS PDMA NOD IN JAPAN FOR FARAPULSE PFA SYSTEMDR REDDY'S FUNNELS USD 620 MILLION IN SWITZERLAND SUBSIDIARYBoston Scientific Corporation, a leading company in the field of global medical technology, stated that it has been granted approval by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan for the FARAPULSE Pulsed Field Ablation (PFA) System. The FARAPULSE PFA System is a new option for treating paroxysmal atrial fibrillation by isolating pulmonary veins, replacing the traditional thermal ablation method."The FARAPULSE PFA System is the most clinically studied PFA system and its use in treating more than 125,000 patients globally to date continues to reinforce its strong safety, efficacy and efficiency profile," said Nick Spadea-Anello, president, electrophysiology, Boston Scientific.AF can increase the chances of dying, having a stroke or heart failure, and it is present in over one million individuals in Japan. The global estimate is that around 38 million people are affected by AF. Contrary to conventional thermal ablation methods for treating AF by applying extreme temperatures to cardiac tissue, the FARAPULSE PFA System utilizes non-thermal electrical fields to prevent harm to nearby structures."Clinical evidence and extensive real-world use have demonstrated the FARAPULSE PFA System to be an efficient and more predictable procedure than traditional thermal ablation and a proven safe technology," said Kazuhiro Satomi, M.D., Ph.D., professor, Department of Cardiology and director, Heart Rhythm Center, Tokyo Medical University Hospital. "This technology has the potential to rapidly advance clinical practice and improve outcomes and is anticipated to further expand the range of treatment options for AF that can be tailored to each patient's condition". PODrug manufacturer Dr Reddy's Laboratories Ltd has invested $620 million into its wholly-owned branch, Dr Reddy's Laboratories SA, Switzerland (DRL SA). This investment is consistent with the company's previous board-approved decision to invest up to ?500 million ($640 million) to purchase the Nicotinell brand and its associated assets from the Haleon Group.DRL SA has released 6.2 million non-convertible preference shares, with a value of $100 each, to Dr Reddy's Laboratories. DRL SA plans to use the funds raised to purchase Northstar Switzerland SARL, the owner of the Nicotinell brand.Investing in DRL SA is considered a related party transaction because it is fully owned by Dr Reddy's. Nevertheless, the investment was carried out relying on an appraisal report from an impartial valuer. The deal is carried out at an independent level, without any further involvement from the promoter or promoter group in DRL SA.This year, on June 26, the top pharmaceutical company entered into a final agreement with Haleon lc, a consumer healthcare firm, to acquire shares of its subsidiary Northstar Switzerland SARL. DRL aims to purchase an international collection of consumer healthcare brands for £500 million, excluding those in the United States.DRL is set to purchase Nicotinell, the nicotine replacement therapy (NRT) sector, and associated brands from Haleon Plc. The acquired portfolio's revenue totals £217 million in 2023, £200 million in 2022, and £201 million in 2021. POTOP STORIES
< Page 7 | Page 9 >